P Pharming Group NV
P
Cerrado
1.1 -2.57
Resumen
Variación precio
24h
Mínimo
1.096
Máximo
1.133
Ingresos | -10M -5.1M |
|---|---|
Ventas | -36M 71M |
P/B Media del Sector | 55.3 51.415 |
BPA | 0.01 |
Margen de beneficios | -7.196 |
Empleados | 407 |
EBITDA | -4.8M -2.1M |
Próximas Ganancias | 30 jul 2026 |
|---|
Capitalización Mercado | -227M 781M |
|---|---|
Apertura anterior | 3.67 |
Cierre anterior | 1.1 |
Pharming Group NV Gráfico
Resultados pasados no son un indicador fiable de resultados futuros.
Noticias Relacionadas
Comparación entre iguales
Cambio de precio
Pharming Group NV previsión
Finanzas
Gastos de venta y administración
Gastos operativos
Beneficio antes de impuestos
Ventas
Coste de ventas
Beneficio bruto de ventas
Gasto por intereses de deuda
EBITDA
Beneficio operativo
$
Acerca de Pharming Group NV
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
